CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin


11 May 2015

Putting Alzheimer’s disease to the test: Improving pharmaceutical development and patient outcomes

Professor Barbara Sahakian describes her work developing sensitive assessments of cognition for patients with Alzheimer’s disease, and the application of these tests in academic research, pharmaceutical clinical trials and healthcare settings.

11 May 2015

[Video] Enhancing mental health research

11th-17th May marks Mental Health Awareness Week, watch Professor Trevor Robbins discuss how Cantab has enhanced mental health research.

7 May 2015

[Video] Principles of cognitive safety assessment in clinical development

Watch Dr Kenton Zavitz, Director of Clinical Affairs' talk from the 7th Annual World Drug Safety Congress in Chicago, on the 22nd April 2015.

1 May 2015

CANTAB study identifies blood protein MAPKAPK5 that may indicate cognitive decline

Scientists have identified a single blood protein that may indicate the development of Mild Cognitive Impairment (MCI) years before symptoms appear, a disorder that has been associated with an increased risk of Alzheimer's disease or other dementias.

31 March 2015

Cognitive Research Update - March

New peer-reviewed papers added to the Cantab Bibliography throughout March.

26 March 2015

Crossing the Blood-Brain Barrier: Profiling Cognitive Safety in Clinical Development

The blood-brain barrier (BBB) is a highly regulated and complex layer of cells that has evolved to protect the brain from toxic molecules and infectious agents. Dr Kenton Zavitz, Director of Clinical Affairs explores the crossing of the blood-brain barrier and how to measure and monitor the cognitive effects of drug compounds in clinical trials.